DTIC-Dome (Dacarbazine) for Lymphoma

Overview
DTIC-Dome, also known by its drug name, dacarbazine, is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating Hodgkin lymphoma. DTIC-Dome is often combined with other drugs such as Adriamycin, bleomycin, and vinblastine sulfate in a chemotherapy regimen.

DTIC-Dome is an anticancer drug and a member of a class of drugs called alkylating agents. DTIC-Dome is believed to work by preventing the production of DNA in cells, thereby blocking cell division.

How do I take it?
DTIC-Dome is administered as an intravenous infusion during chemotherapy treatment.

Side effects
The FDA-approved label for DTIC-Dome lists common side effects including flu-like symptoms, nausea, vomiting, numbness or tingling in the extremities, loss of appetite, low blood cell counts, and pain or irritation at infusion site during infusion.

Rare but serious side effects listed for DTIC-Dome include fetal harm in pregnant women and an increased risk for developing other cancers.

For more details about this treatment, visit:

Chemotherapy for Hodgkin Lymphoma — Leukemia and Lymphoma Society
https://www.cancer.org/cancer/hodgkin-lymphoma/...